Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
https://www.nbcnews.com/politics/congress/mcconnell-wants-hemp-removed-controlled-substance-list-n860161
Seems as if the MM walked this down ... That big sale of 39k shares has been lowered every day, which has killed buying into the ask. Thus, allowing someone to accumulate shares much cheaper. Hopefully, it is MNTR executing buy back shares and is the new launch spot for the next big run.
You meant $.10, right? 10 cents?
Do I think it has the potential to reach 10? Yes! Do I know when? No.
Plenty of catalysts pending to drive business:
1. Eight or more states slated to legalize either for recreational or medical.
2. CANADA!
3. U.S. Federal support for decriminalization and/or legalization. (Let the States decide)
4. Further research for Cancer treatments.
ETC. ETC.
What do you think it will get to. 10$?
A long-term 300,000 share repurchase plan was authorized in 2014, and at December 31, 2017, a total of 44,748 shares have been repurchased under the long-term plan.
Very Low Float - Solid Share Structure - Potential for PPS to exceed $2.50 is very realistic IMO!
Mentor Capital, Inc. had approximately 12,000 shareholders reported as of December 31, 2017, with 22,814,283 shares issued. There were 6,666,007 Series D warrants outstanding at the December 31, 2017, year-end at a strike price of $1.60 per share, and 689,159 Series H warrants that are held by an investment bank at a $7.00 per share exercise price. During 2017, Mentor paid for a contractual interest in a legal recovery through the issuance of 288,890 shares of unregistered common stock valued at $600,002. No equity was granted to directors, insiders, consultants or investor relations firms in 2017. A long-term 300,000 share repurchase plan was authorized in 2014, and at December 31, 2017, a total of 44,748 shares have been repurchased under the long-term plan. The Company’s shares finished the year at a closing price of $2.29 per share representing a market capitalization of $52,244,708 compared to a 2016 year ending closing price of $1.06 per share and a corresponding market capitalization of $22,239,341. As of March 29, 2018, the closing price of the Company’s shares was $1.02 with a corresponding market capitalization of approximately $23,538,000.
How high will this go when marijuana is federally legal?
Big sell flashed... (34k @ 1.02) Not sure what that was about...
Even if MNTR goes to $2.00, that is only a measly 7.33x Price/book value.....
This is a no brainer to load at $1.00 and double your money. GLTA
A little buying goes a long way here...
Spike in price and little volume...
For every seller there is a buyer. Trades don’t happen unless there is one of each. Somebody bought a crazy big amount at 14,000 shares today. Dried up any excess shares... in one shot with a little panic selling to boot.
Waiting for the bigger wave up...
Defiantly. The whole sector been hurted past Months. A safe one to around 1.45 at this point.
Agreed. Lots of positive things in the works for MJ.
MJ sector seems primed for rebound. Sealing southern borders and legalized in Canada. Increased demand perhaps?
Pathetic. Even bottom-feeding day-traders ignore Chester Billingsley's $MNTR.
Load low, sell high. Wash, rinse and repeat here.
Good point. Ment Monday as I was hoping to hit this ATM early in the day.
You done very well off those .70'S? Cannot lose here based on any MJ news that will come. If they are quiet buy the dips. News comes, sell the rips.
Wash, rinse and repeat.
Since today is Sunday, I doubt it.
Could today be the MNTR dip and rip all. Be ready here for a strong sell off to get back on the ATM train.
News: New York looking to Legalize Recreational MJ!
I do believe that that's one state looking to legalize per day.
This study will be conducted to see what steps need to be conducted when they do legalize. This comes on the back of New Jersey's recreational marijuana legalization thanks to the transition of governorship from Chris Christie to Phil Murphy.
https://www.democratandchronicle.com/story/news/politics/albany/2018/01/16/new-york-look-legalizing-recreational-marijuana/1036703001/
All bullish IMO!
Bipartisan Bill Could Free States MJ by Jan 19
https://www.forbes.com/sites/janetwburns/2018/01/15/bipartisan-re-f-e-r-bill-targets-sessions-war-on-cannabis-in-high-style/#3cf34c1f7399
Nearly 70 Congress members push protection bill
http://www.thecannabist.co/2018/01/12/congress-protect-marijuana-mcclintock-polis/96679/
All bullish IMO
New Congressional Bill Handcuffs Sessions’s Enforcement
https://www.marijuanamoment.net/new-congressional-bill-handcuffs-sessionss-marijuana-enforcement/
Good grief, play the movement in the otc. Risk to reward is incredible when you hit these at 10-20 times your money. MNTR is easy and not sure why you missed the action from .70.
Do not get made at the players if you do not understand the game.
If you find yourself at a poker game and did not figure out who the sucker is in 15 minutes,,, it is you.
Simply wait for the pullback 20-50%.
WHERES THE BUY IN PRICE? tia
Exactly and makes for great movement in a otc stock. This is a favorite of many and hope you did really well as well with MNTR.
Up 200% in a blink. Now wait for this to settle again and get back on the money train.
You see the stock price on MNTR. Maybe play the action and not fall in love with a otc company.
Good grief make money and have fun. MNTR is so easy to play a caveman could do it.
Bhang didn't steal from MNTR. They were conned by MNTR.
Just like Chester has been conning the market with his BS.
1) Vape patent. They never had an patent, only a flimsy and now worthless application. PS There is no such thing as an "international" patent
2) Chester doesn't have 2 million coming in from the courts, He has around $1.7 coming because he was forced to buy stock back by the AAA ruling. Stock that was later found by the Federal court to be issued without proper authorization aka "unregistered securities"
3) Chester knew about the fraud on the loan and the credit default insurance long before he notified the trading public.
4) The 600k from the credit default insurance is still in the wind. Made a big deal of getting a judgment, but dent mention it again. Why? Are you actually pursuing it?
5) stretched truths, half truths and worst of all flat out lies. It is the CB way.
Vermont, N.H., N.J., Michigan to Legalize!
https://www.forbes.com/sites/tomangell/2018/01/09/new-hampshire-lawmakers-approve-marijuana-legalization/#18dba252a426
http://www.app.com/story/news/local/communitychange/2018/01/09/nj-marijuana-legalization-asbury-park-dispensaries/1003912001/
https://www.forbes.com/sites/tomangell/2018/01/04/vermont-lawmakers-approve-marijuana-legalization-bill/#556fef9243b7
https://www.420magazine.com/news/international-cannabis-news/vermont-new-jersey-michigan-states-looking-legalize-marijuana-2018/
"You can't trust this so called CEO Chester the company stock molester he's got to GO the sooner the better along with the board of directors that watch and do NOTHING"
From Yahoo Finance
Do due diligence
Trash, MJ or anything they want to keep the movement up and down and up is OK with me. I may put a picture of Chester on my office wall soon from the money he's made us.
The swings on this in incredible. Even a caveman could make money here.
Same here. 2.06 now. We told them.was pretty obvious.
So from 1.20 yesterday to 1.98 today. Another stellar day and MNTR ATM is strong.
heading to 52 wk.high for a simple reason, on much better shape than a year ago (4.82 pps). revenues, cash, the balance sheet and California approval
99% of MNTR income is from Trash Management.
Read its Form 10-Q (from its 11-09-17 filing).
Do due diligence.
Cali. grower. MNTR very rare to find a weed company generating revenues (increasing) and has the most solid balance sheet the entire sector( assets/liabilities ratio=7)
Just received $2m in cash and MC very low compare the industry.
$MNTR has to prove to shareholders it can make money in ways other than suing companies that steal from them due to a lack of DD.
JD @Kalidewar Jan 3
From $MNTR Twitter feed
Unlike Chester, do perform due diligence
holy smokes Chester sells this every chance he gets at any price... he must not have any faith in this company.... it's mind boggling how many shares he sells every month
Chad
22 hours ago
From the Yahoo Finance MNTR Conversation Board
Do die diligence
You get some of those MNTR 1.20-130's? You should have done well off those .70's.
This is becoming a bigger ATM with the movement and please tell me you knocked it out of the park these last 2-3 moves. Was the easiest I seen in awhile.
Followers
|
131
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3662
|
Created
|
02/15/10
|
Type
|
Free
|
Moderators |
Authorized Shares 75,000,000 02/05/2021 Outstanding Shares 22,730,793 02/05/2021 Float 19,883,188 11/04/2020 |
| | |
VIDEOSCannabis: Harvesting the 600% Growth, Without Taking a Hit |
Management Today Magazine: Click to Read Full Article Portfolio & Investments |
Metro Capital, Inc. (MNTR) is a public company that invests in medical and social use cannabis companies. Mentor takes a 10% to 60% position in the family of participating companies, but leaves operating control firmly in the hands of the cannabis company founders. Because adult social use and medical marijuana opportunities often overlap, Mentor Capital also participates in the legal recreational marijuana market. However, Mentor’s preferred focus is medical, and the company seeks to facilitate the application of cannabis to cancer wasting, calming seizures and Parkinson disease, reducing ocular pressures from glaucoma, and blunting chronic pain.
Mentor’s approach and capital structure allows its shareholders to buy an additional $140 million of Mentor shares at approximately a 12.5% discount. As money is sent in to buy into the growing cannabis portfolio, the proceeds are split pro rata amongst the cannabis companies that are participating in the indirect sale in order to receive funding. As more private cannabis companies join in the consortium, the higher the MNTR share price is pushed, other things being equal. The increasing share price increases the exercise of stock options and warrants by both Mentor Capital’s 1,500 mostly accredited shareholders and the public market in general. Using this approach, Mentor can deliver a higher price to founders for a smaller slice of their business. Retaining control and receiving more cash are the two key advantages to cannabis founders working with Mentor Capital, Inc.
Only 3% of the illegal marijuana market has, at the beginning of 2014, been shifted into the legal sector. This implies a 30x potential increase in the size of the cannabis market upon the eventual realization of a federal lifting of the prohibition on cannabis, if lifted for both medical and adult social use. The 30x implied illegal to legal potential market shift may be one factor in why the market capitalization sof some public cannabis companies are in the 30x revenue (i.e. sales) range. The $1.4 Billion legal cannabis market is forecast to grow by 63% during 2014. It is important to note that this 63% annual increase in sales or even the entire 30x potential increase requires no true growth in the overall cannabis market or other growth in cannabis usage. The modeled growth is satisfied, in our understanding, by the shifting of cannabis buyers to legal sellers rather than them risking buying through any remaining illegal channels. The $50 Billion market already exists and does not need to be developed, just shifted over. Antidotal evidence in Denver indicates that illegal channels are already expressing resentment toward the decline in street sales because of the shift to legal, controlled cannabis sale.
To lead and capture a major portion of the potential 30 times increase in the legal cannabis market Mentor Capital's investing strategy is:
1) Be first with significant public money
2) Quickly roll up the best cannabis participants in a public vehicle
3) Bring a high level of character and business professionalism to the marijuana investing sector
Mentor is authorized (almost like a group IPO) to raise $140 million from the public market and is committing those funds to the cannabis companies that join in the cooperative portfolio, trading a slice (10% to 60%) of their business in exchange for public market funding. To Mentor's knowledge, Mentor Capital is the first public company to commit this level of a cash raise to the cannabis market.
In any very rapidly growing situation, companies need large amounts of capital to keep pace with the growth opportunity. It is hoped that the cannabis firms Mentor funds will have a significant advantage in absorbing a large share of the expected business expansion.
In order to apply the $140 million fully and quickly, Mentor Capital has been very aggressive in recruiting cannabis companies to secure their share of a funding portfolio. A very high price in future proceeds is offered, against the backstop of starting within a $1.4 Billion legal market and looking to expand to encompass the $50 billion already existing illegal market, all implying a 30x market growth.
The current public market multipliers are in the 30x to 80x revenues range. This, quite possibly because there is a projected near term market growth of 30 times. Almost any reasonably solid, well-financed company will do well in this sort of environment. Mentor is quite experienced in picking solid companies and even very high offers will still be much less than 30x revenues. This all gives encouragement to green light a roll up of the best available cannabis companies in each sector and region. This investment and acquisition approach may have an expectedly high return but surprisingly low business risk, in our examination.
A final plank in the Mentor Capital investment strategy is qualitative and is pushing to bring a high degree of business professionalism and transactional integrity to the marijuana public market. As a first, the CEO voluntarily placed all of his MNTR shares in escrow with a law firm. This, to address the widespread concerns that pump and dump schemes are prevalent in the medical marijuana market. Additionally, the CEO is taking the role of the non-user, designated driver in this cannabis industry involvement. Finally, following from the West Point, Harvard, General Electric formal approach to the world, all interactions are structured to be 100% business and win-win-win. In an open way all business transactions should be a win for Mentor, for cannabis founders, and the investing public.
This formal, win-win-win, all business approach is a natural one for Mentor Capital. Management hopes in this way to attract the cannabis founders of the best cannabis brands. These founders are brought together with conservative investors who are still looking for a solid business approach within this extraordinary opportunity.
Chester Billingsley is a native of Minnesota, born in 1952. He received a congressional appointment and did his undergraduate work at West Point. Later he went to graduate school at Harvard University where he received a Master’s Degree in Applied Physics with concurrent study at Harvard Business School and at MIT studying proton radiology as applied to difficult to treat cancers, in conjunction with Mass General Hospital.
Mr. Billingsley spent the major portion of his early career at General Electric in technical sectors in project, turn-around and international management positions. In 1985 he formed Tech Start, the predecessor to Mentor Capital in the heart of Silicon Valley. He has held the general manager or president position since that time.
In 1995 he took the firm public and has had lead responsibility in the Tech III Partners, Cambridge Equity Partners, and Mentor Investors I, LP financial partnerships. He has directed the successful acquisition or investment in thirty-six operating business or entities.
Mr. Billingsley is a conservative, 61 years old, non-using businessman. In August 2013, he led the surprising but science-based decision to take Mentor Capital into the medical marijuana space. The goal was to pursue an alternative approach to fighting cancer while seeing significant shareholder returns.
As a public company pioneer in the legal cannabis space, Mr. Billingsley became a founding director and officer of the board of directors of the Nevada Cannabis Industry Association in November 2013.
Market Value1 | $12,196,693 | Jan 17, 2014 |
Shares Outstanding | 6,419,312 | Sep 30, 2013 |
Float | 1,545,670 | Sep 30, 2011 |
Authorized Shares | 400,000,000 | Sep 30, 2013 |
Shareholders of Record | 1,561 | a/o Sep 30, 2011 |
Mentor Capital (MNTR) Invests in Leading-Edge Cancer Therapy & Drug Development Companies
Filings
http://www.otcmarkets.com/stock/MNTR/filings
Summary Data. Management Team. Professional Support. Philosophy.
Ethics. Corporate Governance.
http://www.mentorcapital.com/About-Mentor-Capital.html
Portfolio Companies
Advaxis, Inc. (ADXS)
Advaxis is a biotechnology company that uses a harmless bioengineered bacterium, Listeria monocytogenes to activate the immune system to treat cancer. A vaccine of incapacitated bacteria infiltrate cancer cells. The body attacks the cells containing or marked by the bacteria, killing the cancer cells.
Antigenics (AGEN)
Biotechnology company developing cancer vaccines and other treatments for cancer and infectious diseases.
BioVest International, Inc. (BVTI)
Biovest International develops personalized immunotherapies for life threatening cancers of the blood system.
Celldex Therapeutics, Inc. (CLDX)
Celldex Therapeutics is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases.
CEL-SCI (CVM)
CEL-SCI is dedicated to improving the treatment of cancer and other diseases by unleashing the power of the immune system; the body's natural and most potent defense system.
Dendreon (DNDN)
To target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer.
Generex Biotechnology Corporation (GNBT)
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs).
Hadron Systems, Inc. (Private)
Widely recognized by cancer immunologists is the communicative role of tumor stromal cells that shield tumors from the immune system, and the potential of vaccines with inhibiting properties. Hadron Systems, Inc. - a privately held company - represents the targeting and ablation of tumor stroma via targeting/nucleus internalization in combination with particle therapy (the product). The product is classified as a medical device, and a clinical trial to include late-stage cancer patients is planned for September 2012.
ImmunoCellular Therapeutics, Ltd. (IMUC)
ImmunoCellular Therapeutics, Ltd. (OTC:IMUC.OB) We are a clinical-stage company that is focused on developing new therapeutics to fight cancer using the immune system. Our product pipeline includes peptide based vaccine to target cancer stem cells, cellular immunotherapies to target cancer associated antigens, and monoclonal antibodies to diagnose and treat several different cancers. Our main disease focus using our immunotherapy technologies is to treat glioblastoma, but these therapies may also be applicable to multiple other cancers such as pancreatic, colon and breast cancers due to presence of similar epitopes on these malignant cells. Our antibodies are designed to treat small cell lung cancer, pancreatic cancer, multiple myeloma and ovarian cancer.
Northwest Biotherapeutics, Inc. (NWBO)
Northwest Biotherapeutics, Inc. is a development stage biotechnology company focused on discovering, developing and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer.
Oncothyreon (ONTY)
Oncothyreon is a biotechnology company dedicated to the development of oncology products that can improve the lives and outcomes of cancer patients.
Provectus Pharmaceuticals, Inc. (PVCT)
Provectus Pharmaceuticals, Inc., with its home office in Knoxville, Tennessee, is developing advanced prescription drugs in the fields of oncology and dermatology. Clinical trials of our cancer drug PV-10 for the treatment of melanoma, breast cancer, and liver cancer are currently being conducted. PH-10, our topical formulation of Rose Bengal, is also in clinical trials for psoriasis, atopic dermatitis, and eczema.
MNTR's objective is to help defeat cancer by funding $125 Million into the best new cancer fighting companies. MNTR equity is targeted to the critical gap between non-profit discovery and Big-Pharma sales.
To inject funds into the cancer companies (rather than trade in the market) MNTR seeks to directly acquire and escrow $125 Million in shares from fifteen Cancer Index or other leading firms. Any resulting net exercise in MNTR's $125 Million in freely tradable warrants are paid out pro rata to the cancer fighters under MNTR's standard Long-Term Equity Funding Contract.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |